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Abstract This study employs spectroscopy-based meta-
bolic profiling of fecal extracts from healthy subjects and
patients with active or inactive ulcerative colitis (UC) and
Crohn’s disease (CD) to substantiate the potential use of
spectroscopy as a non-invasive diagnostic tool and to
characterize the fecal metabolome in inflammatory bowel
disease (IBD). Stool samples from 113 individuals (UC 48,
CD 44, controls 21) were analyzed by 1H nuclear magnetic
resonance (NMR) spectroscopy (Bruker 600 MHz, Bruker
BioSpin, Rheinstetten, Germany). Data were analyzed with
principal component analysis and orthogonal-projection to
latent structure-discriminant analysis using SIMCA-
P ? 12 and MATLAB. Significant differences were found
in the metabolic profiles making it possible to differentiate
between active IBD and controls and between UC and CD.
The metabolites holding differential power primarily
belonged to a range of amino acids, microbiota-related
short chain fatty acids, and lactate suggestive of an
inflammation-driven malabsorption and dysbiosis of the
normal bacterial ecology. However, removal of patients
with intestinal surgery and anti-TNF-a antibody treatment
eliminated the discriminative power regarding UC versus
CD. This study consequently demonstrates that 1H NMR
spectroscopy of fecal extracts is a potential non-invasive
diagnostic tool and able to characterize the inflammation-
driven changes in the metabolic profiles related to malab-
sorption and dysbiosis. Intestinal surgery and medication
are to be accounted for in future studies, as it seems to be
factors of importance in the discriminative process.
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bowel disease  Metabolomics  NMR spectroscopy
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Ulcerative colitis (UC) and Crohn’s disease (CD) are the
two main entities under the umbrella diagnosis of chronic
inflammatory bowel disease (IBD). These two similar, yet
distinct diseases are believed to be the consequence of an
unbalanced immunological response towards intestinal
microbes or components hereof in genetically predisposed
individuals (Baumgart and Sandborn 2012; Orda´s et al.
2012). However, despite of our current knowledge and
understanding, the etiology and exact pathophysiology
largely remain unknown. The diagnostics of IBD is based
on a multidisciplinary approach (clinical history, endos-
copy, radiology, histology, microbiology, and hematol-
ogy), which is disadvantaged by its invasive nature, its time
consuming procedures, and the fact that it leaves *10 %
of the patients with the diagnosis of ‘‘IBD unclassified’’
(IBDU) (Geboes et al. 2008). The diagnostic delay (Va-
vricka et al. 2012) and lack of differential power (i.e.
IBDU) imposes serious clinical implications, as early and
correct diagnosis is important both for the patients’ quality
of life as well as for a successful clinical management
(Etchevers et al. 2008; Ricart et al. 2008).
New technologies have recently been put into play and
as a consequence transcriptomics (Bjerrum et al. 2010a;
Olsen et al. 2009; Sipos et al. 2011; von Stein et al. 2008;
Wu et al. 2007; Bjerrum et al. 2013; Planell et al. 2013),
metabonomics, (Bjerrum et al. 2010b; Balasubramanian
et al. 2009; Schicho et al. 2012; Williams et al. 2012;
Bezabeh et al. 2001; Bjerrum et al. 2008; Zhang et al.
2013; Ooi et al. 2011) and integration of omics (Bjerrum
et al. 2014) have produced promising results with respect to
refinement and improvement of the diagnostics and
understanding of the pathophysiology of IBD. The draw-
back is, however, that the majority of these studies are
based on sample types acquired via invasive or semi-
invasive procedures (e.g. endoscopic pinch biopsies, sur-
gically removed colonic tissue, or blood). Non-invasive
tests are badly needed for the diagnostics and the surveil-
lance of the disease activity. Such tests would provide a
higher degree of compliance in this patient population and
ultimately it might lead to a better disease control for the
individual patient with IBD.
With the intention to identify metabolic biomarkers and
explore the possibilities of developing non-invasive tests,
metabonomics studies have used urine samples from
experimental animal IBD models (Murdoch et al. 2008; Lin
et al. 2009; Dong et al. 2013; Schicho et al. 2010; Tso et al.
2013) and IBD patients (Williams et al. 2009; Schicho
et al. 2012; Bjerrum et al. 2010b; Stephens et al. 2012;
Dawiskiba et al. 2014) as an easily collected and handled
sample type. The results so far have been promising but
also conflicting. By contrast, it is well known that the gut
microbiota differs between CD, UC, and controls (Sartor
2008), and as a consequence the preliminary metabonomics
studies (Marchesi et al. 2007; Jansson et al. 2009; Le Gall
et al. 2011; Walton et al. 2013) using metabolic profiles of
fecal extracts have consistently been able to differentiate
between IBD and controls as well as between IBD
subtypes.
These promising preliminary results—together with the
much needed non-invasive tests—animated the initiation of
the current study in which we aimed to employ 1H nuclear
magnetic resonance (NMR) spectroscopy-based metabolic
profiling of fecal extracts from healthy subjects and
patients with active or inactive UC and CD. This was
performed to substantiate the potential use of 1H NMR
spectroscopy as a non-invasive diagnostic tool and to
characterize the fecal metabolome in IBD.
2 Materials and methods
2.1 Patient population
All patients participated in this study in confirmation with
the principals outlined in the Declaration of Helsinki and
with the approval of the Scientific Ethics Committee of the
Copenhagen Capital Region (22 054/H-C-2009-037).
Informed written consent was obtained from each partici-
pating person.
Patients were recruited at the Department of Gastroen-
terology, Medical Section, Herlev Hospital, Denmark. All
eligible UC (n = 48) and CD (n = 44) patients subse-
quently had their diagnosis verified by well-established
criteria (Nikolaus and Schreiber 2007) and were at the time
of enrolment graded in accordance with the Mayo-score
(Schroeder et al. 1987) (a score of 0–1 inactive UC, 2–4
mild UC, 5–8 moderate UC, and 9–12 severe UC) or
Harvey-Bradshaw-score (Harvey and Bradshaw 1980) (a
HB-score score of 0–4 inactive CD, 5–8 mild CD, 9–16
moderate CD, and[16 severe CD). See Table 1 for clinical
details.
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The healthy volunteers (n = 21) were recruited locally
among the staff at Herlev Hospital—in all 113 individuals
were included. Exclusion criteria were age above 80 or
below 18 years, clinical evidence of infection, recent
(within 14 days) use of antibiotics or probiotics, preg-
nancy, severe mental illness and special food regimens
such as FODMAP, diabetic diets, and gluten-free diet.
2.2 Sample collection and preparation
Each participant was given a sample collection kit with
instructions. Hence, one fecal sample from each subject was
collected, placed in a sealed insulate container, immediately
put on ice, and subsequently delivered to the laboratory within
3 h, where it was stored at -80 C. Previous experiments
(Bezabeh et al. 2009) using un-extracted raw samples pro-
duced spectra with a poor resolution, whereas Marchesi et al.
(2007) and Jacobs et al. (2008) achieved excellent results with
water extracts and a pH above 7. Hence, fecal water was
extracted by taking a weighed sample of thawed stool material
and adding 2 volumes (w/v) of sterile phosphate buffered
saline (PBS 1.9 mM Na2HPO4, 8.1 mM NaH2PO4, 150 mM
NaCl, pH 7.4). The mixture was homogenized by vortexing
vigorously for 1 min. The fecal slurry was centrifuged at
3,0009g for 15 min, and the supernatant was filtered through
a syringe with a needle (0.40 9 25 mm). The filtrate was
centrifuged at 14,0009g for 30 min, and the supernatant fil-
tered through a Whatman 25 mm GD/X PES sterile syringe
filter (pore size 0.2 lm). The filtered fecal water was stored at
-80 C until subsequent analysis.
The fecal extracts were finally prepared by mixing 4 ll
of D2O/500 lM TSP (3-trimethylsilyl-2,2,3,3-tetradeute-
rosodium propionate, final TSP = 50 lM) with 40 ll of
fecal extract in a 96-hole shallow hole plate. A total of
35 ll from each of these mixed samples were transferred
into 1.7 mm outer diameter NMR tubes in a SampleJet rack
used for the NMR experiments. Previous investigations on
fecal extracts have shown no marked changes in the reso-
nances of interest as a result of the freeze/thawing cycle
(Bezabeh et al. 2009; Saric et al. 2008).
Table 1 Clinical details
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Characteristics n = 31 n = 13 n = 29 n = 19 n = 21
Gender (male/female) 13/18 6/7 14/15 11/8 13/8










Age at diagnosis (B25/[25 years) 10/21 8/5 5/24 3/16 –
Years with disease (B10/[10 years) 16/15 9/4 12/17 14/5 –
HB-score (mean, range) 1 (0–4) 10 (5–18) – – –
Mayo-score (mean, range) – – 0.3 (0–1) 7 (3–11) –
Extension (P/PS/LC/PC/Ileit) – 2/2/3/1/9 – 1/2/4/11/0 –
Surgery (IR/IR?HC/HC/C) 6/2/2/3 3/2/1/1 0/0/1/2 0/0/0/0 –
Smoking/non-smoking 9/22 5/8 7/22 2/17 2/19
EIM (present/not present) 6/25 1/12 1/28 1/18 –
Steroids, n
Responder/non-responder/unknown 24/0/7 9/3/1 17/2/10 14/3/2 –
Independent/dependent/unknown 21/3/7 4/8/1 17/2/10 10/7/2 –
Daily medication, n
Sulfasalazine (1.5–2.0 g) 1 0 2 1 –
Systemic 5-aminosalicylic acid
(1.6–3.2 g)
2 0 24 17 –
Topical 5-aminosalicylic acid (1 g) 0 0 5 11 –
Systemic glucocorticoids (75 mg) 1a 4 2a 10 –
Topical glucocorticoids (100 mg) 0 1 1 3 –
Azathioprine (100–150 mg) 9 3 2 0 –
6-Mercaptopurine (50–75 mg) 1 0 1 0 –
Infliximab (5 mg/kg) 3 4 1 0 –
None 17 3 2 0 21
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2.3 1H NMR spectroscopy
All 1H NMR experiments were performed at 288.1 K,
using a Bruker 600 MHz spectrometer operating at
600.13 MHz for proton and equipped with an inverse
detection cryogenic probe (BrukerBioSpin, Rheinstetten,
Germany). For all samples, the 1H NMR spectra were
acquired using a CPMG (Carr-Purcell-Meiboom-Gill)
pulse sequence with an echo-time of 160 ms. The 90 pulse
length was approximately 10 ls as calculated automati-
cally for each sample. A total of 256 scans were collected
into 32 k data points with a spectral width of 12 ppm.
NMR resonances were assigned according to previous
published data (Marchesi et al. 2007).
2.4 Data analysis
The free induction decays for one-dimensional data were
zero-filled to 64 k data points and multiplied by an expo-
nential function with a line-broadening factor of 0.5 Hz
prior to Fourier transformation. All one-dimensional 1H
NMR spectra were manually corrected for phase and base-
line distortions using TOPSPIN 2.1(BrukerBiospin) and
referenced to the TSP signal at d 0.0 ppm. 1H NMR spectral
regions d 0.5–9.0 were binned with a width of 0.004 ppm
(2 Hz) using the AMIX package (v3.9.3, BrukerBiospin).
Water regions d 4.4–5.2 were removed in order to avoid
imperfect water saturation. Additionally, all UC patients
were treated with 5-aminosalicylic acid; hence the reso-
nances from 5-aminosalicylic acid and its metabolite, N-
acetyl-5-aminosalicylic acid, which include the entire aro-
matic region and d 2.12–2.26, were removed whenever
group comparisons involved UC patients. For the compar-
isons between CD and controls, two samples contained
5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid
and these samples were excluded from the analysis. The
decision to exclude the two CD samples and thus keep the
aromatic region in the remaining CD samples, as opposed to
the UC samples, is based on the principle of keeping as
many data as possible in order to generate valid results.
The 1H NMR spectra were normalized to the total sum
of the spectral integrals to compensate for sample con-
centration differences. Subsequently, the multivariate data
analyses were carried out using the SIMCA-P ? software
package (v12.0, Umetrics, Umea˚, Sweden). Initially, the
principal component analysis (PCA) of the 1H NMR
spectral data was performed (on mean-centered data) to
visualize the general structure of each data set and to
identify any abnormalities (based on the principles of
Hotelling T2) within the data set. Next, the supervised
multivariate methods, projection to latent structure-dis-
criminant analysis (PLS-DA) and orthogonal-projection to
latent structure-discriminant analysis (O-PLS-DA)
(Bylesjo¨ et al. 2006) was applied to the analysis of 1H
NMR spectral data scaled to unit variance (UV) in order to
uncover metabolic differences. O-PLS is an extension of
the partial least square regression method featuring an
integrated orthogonal signal correction filter (Trygg and
Wold 2002). The interpretation of the model is facilitated
by a back-scaled transformation of the loadings, with
incorporated color-coded correlation coefficients (MAT-
LAB v7.1, The MathWorks Inc, Natick, MA, USA) of the
metabolites responsible for the differentiation as described
by Cloarec et al. (2005). In short, each back-scaled loading
is plotted as a function of the respective chemical shift with
a color code that indicates the weights of the discriminatory
variables. A hot color (red) corresponds to the metabolite
being markedly different between classes, while a cool
color (blue) corresponds to no differences between classes.
In order to validate and avoid the risk of over-fitting the
PLS model, a sevenfold cross-validation was used, i.e.
iterative construction of models by repeatedly leaving out
one-seventh of the samples, and predicting them back into
the model. This procedure results in a cross-validation
parameter Q2, indicating the predictability of the model in
relation to its statistical validity. An additional cross-vali-
dation tool, a permutation test, was performed for each
model: 200 models were constructed with the use of ran-
domized classification for the samples and Q2 generated
from these models were compared to the Q2 of the real
model. If the maximum value of Qmax
2 from the permuta-
tion test was smaller than the Q2 of the real model, the
model was regarded as a predictable model. Similarly, the
R2 was used to evaluate possibly over-fitted models. A final
significance test was performed with the use of a CV-
ANOVA (analysis of variance of the cross-validated
residuals) (Eriksson et al. 2008) test to verify the models
validity. The models were only considered to be valid if the
permutation test and the CV-ANOVA test were satisfied at
the same time.
In order to determine the sensitivity and specificity of
the established models receiver operating characteristic
curves (ROC) of true positive rates were plotted as a
function of false positive rates in SPSS using cross-
validated Y prediction values. The subsequent areas of
under the ROC curves were also calculated in SPSS.
3 Results
3.1 1H NMR spectra of fecal extracts
Typical 1H NMR spectra of fecal extracts obtained from
controls and active and inactive CD and UC patients are
shown in supplementary material 1. A range of endoge-
nous metabolites observed in the spectra are similar to
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previously detected metabolites (Le Gall et al. 2011;
Jansson et al. 2009; Marchesi et al. 2007), and include a
number of amino acids, such as leucine, isoleucine,
valine, lysine, alanine, tyrosine, phenylalanine, glycine,
glutamate, and aspartate, and the microbiota-related
metabolites including butyrate, propionate, and lactate.
Furthermore, the exogenous metabolites 5-aminosalicylic
acid and N-acetyl-5-aminosalicylic acid were detected in
the samples from UC patients and in two CD samples,
and originated from the medication Mesalazine taken by
all of the UC patients and two CD patients (Table 1).
Subsequent analyses indicated that formate, fumerate,
phenylalanine, and tyrosine were all present in the
excluded regions.
Table 2 Validation of PLS-DA and O-PLS-DA models
CV-ANOVA (p-value) Permutation (n = 200)
A) Models
Active UC vs. inactive UC 0.0160 H X
Active UC vs. controls 0.0006 H H
Inactive UC vs. controls 0.0297 H X
Active UC vs. active CD 0.1083 X X
Inactive UC vs. inactive CD 0.0018 H H
Active CD vs. inactive CD 0.2101 X X
Active CD vs. controls 0.0009 H H
Inactive CD vs. controls 0.0035 H H
B) Models corrected for pouch/ileostomy
Active UC vs. inactive UC 0.0013 H H
Active UC vs. controls 0.0006 H H
Inactive UC vs. controls 0.0065 H X
Active UC vs. active CD 0.0973 X X
Inactive UC vs. inactive CD 0.0001 H H
Active CD vs. inactive CD 1.0000 X X
Active CD vs. controls 0.0045 H H
Inactive CD vs. controls 0.0191 H X
C) Models corrected for intestinal surgery
Active UC vs. inactive UC 0.002 H H
Active UC vs. controls 0.000 H H
Inactive UC vs. controls 0.013 H X
Active UC vs. active CD 0.698 X X
Inactive UC vs. inactive CD 0.317 X X
Active CD vs. inactive CD 0.287 X X
Active CD vs. controls 1.000 X X
Inactive CD vs. controls 0.128 X X
The models were only considered valid if the permutation test and the CV-ANOVA test (p \ 0.05) were satisfied at the same time—italicized
text
A) The models are based on all samples except for 10 excluded samples: 9 outliers of which 2 had an ileostomy and 4 had segmental surgery, and
the three remaining outliers could not be connected to any clinical demographics. The last excluded sample was due to overlapping drug
metabolites. Remaining number of patients: inactive UC: n = 25, active CD: n = 11, inactive UC: n = 27, active UC: n = 19, controls: n = 21
B) The models are based on all samples except for 11 excluded samples: 7 IBD patients with an ileostomy, 1 inactive UC patient with a pouch,
and 3 outliers. Remaining number of patients: inactive UC: n = 25, active CD: n = 11, inactive UC: n = 25, active UC: n = 19, controls:
n = 21
C) The models are based on all samples except for 25 excluded samples: 23 IBD patients with any kind of intestinal surgery and 2 outliers.
Remaining number of patients: inactive UC: n = 17, active CD: n = 6, inactive UC: n = 25, active UC: n = 19, controls: n = 21
CD Crohn’s disease, CV-ANOVA analysis of variance of the cross-validated residuals, O-PLS-DA orthogonal-projection to latent structure-
discriminant analysis, UC ulcerative colitis
H valid model
X invalid model
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3.2 Multivariate data analysis of 1H NMR spectra
PCA was initially applied to the NMR spectra acquired
from the fecal extracts using data scaled to UV. Based on
the principals of Hotelling T2 (95 % confidence limit) a
total number of 9 samples had to be removed (2 had an
ileostomy, 4 had segmental surgery, and 3 could not be
connected to any clinical demographics) and one sample
was excluded due to overlapping drug metabolites, in all 10
samples were excluded.
In order to classify the samples PLS-DA models com-
paring controls with active and inactive UC and CD,
respectively, UC and CD (i.e. active UC vs. active CD,
inactive UC vs. inactive CD), and different disease states
(i.e. active UC vs. inactive UC and active CD vs. inactive
CD) were generated; CPMG NMR data as an X matrix and
class information as the Y variables (Cloarec et al. 2005),
i.e. control, active UC, inactive UC, active CD, and inac-
tive CD. To uncover the metabolic changes holding dif-
ferential power, the O-PLS-DA strategy was subsequently
applied to each model. The O-PLS-DA models were con-
structed with one PLS component and one orthogonal
component for each model. Each model was subsequently
validated with the use of a permutation test (for the PLS-
Fig. 1 OPLS-DA score plots.
The score plots (a, b, c, and
d) are based on the four valid
models containing all patients
and display the 1st PLS
component and one orthogonal
component for each model. A
two-way separation of the fecal
samples is demonstrated in all 4
plots. Blue diamonds control;
empty triangles active CD; red
dots inactive CD; empty circles
active UC; purple stars: inactive
UC. The corresponding back-
scaled loading plots reflect the
class differences in the NMR
spectra. Upright peaks indicate
a relatively increased intensity
of metabolites, and downright
peaks a decreased intensity of
metabolites. The colors shown
on the plot are associated with
the significance of metabolites
in separating the samples as
shown on the right hand side of
the plot, where the color-scaling
map is given together with the
respective correlation
coefficients. In accordance with
the sample number in each
group and a significance level of
p \ 0.05, the metabolites are
significant at correlation
coefficient values above a 0.55,
b 0.43, c 0.44, and d 0.38,
respectively. CD Crohn’s
disease; UC ulcerative colitis;
ala alanine; asp aspartate; buty
butyrate; glu glutamate; gly
glycine; ileu isoleucine; lac
lactate; leu leucine; lys lysine;
phe phenylalanine; prop
proprionate; tyr tyrosine; val
valine (Color figure online)
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DA models, see supplementary material 2) and a CV-
ANOVA (for the O-PLS-DA models).
As seen in Table 2A four of the models met the vali-
dation requirements when the data analyses were per-
formed on all five groups. However, 6 of the 10 excluded
samples originated from patients having had intestinal
surgery, indicating that surgery might have a significant
impact on the fecal metabolome. Predictive models, i.e.
PLS-DA and O-PLS-DA, were consequently generated in
order to further characterize the impact of different surgical
interventions. Patients who had a colectomy were identified
and removed from the analysis: one patient had a pouch
(inactive UC) and seven patients had an ileostomy (4
inactive CD, 2 active CD, and 1 inactive UC) of which only
two patients received TNF-a inhibitor treatment (1 inactive
CD and 1 active CD). Removing these 8 samples resulted
in the model comparing control with inactive CD becoming
invalid, whereas the model comparing inactive UC with
active UC became valid, Table 2B. Subsequent removal of
the remaining patients (coincides with removal of all 8
patients receiving anti-TNF-a antibody treatment), who
also had intestinal surgery, but maintain a continuous
gastrointestinal tract with a partially preserved colon,
resulted in further drastic changes in the predictive models:
inactive UC vs. inactive CD and active CD vs. controls also
became invalid. Only two models met the final validation
requirements, Table 2C. The corresponding score-plots and
their back-scaled loading plots are shown in Fig. 1 (all
samples) and Fig. 2 (samples from patients with intestinal
surgery excluded), where a clear separation between each
class is seen in the score-plots. The corresponding back-
scaled loading plots reflect the class differences of the
NMR spectra and indicate relatively increased or decreased
intensities of metabolites. These back-scaled loading plots
were converted into comprehensive lists of markedly up-
and down-regulated metabolites in Table 3 (3A all patients
included and 3B intestinal surgery patients excluded). The
significant metabolites proposed from the correlation
coefficients were further validated and compared with the
use of a simple Student’s t test and by ANOVA and sub-
sequently corrected for multiple testing using Bonferroni
and Tamhane, respectively (Table 3). The actual prediction
performance estimates are presented in Table 4 as area
under the curve (AUC) and correlates with the results of
the OPLS-DA models; only the models active UC vs.
inactive UC and active UC vs. controls demonstrate AUC
[80. The AUCs are presented in supplementary material 3.
Furthermore, predictive models were generated within
each disease phenotype (inactive CD, active CD, and
inactive UC) comparing patients with and without intesti-
nal resection. However, none of these models were pre-
dictive (data not included). A similarly approach was
applied to the group of inactive CD patients; 17 of these
were medication free, thus providing an opportunity to
elucidate on the potential effect of medication on the fecal
metabolome. The group of inactive CD patients was
accordingly sub-divided into four classes: (1) without
surgery and no medication (n = 10), (2) without surgery
but on medication (n = 8), (3) with surgery but no medi-
cation (n = 7), and (4) with surgery and on medication
(n = 6). These four classes were as previously described
compared with predictive modeling, but none of them
turned out to be valid, although a trend (p = 0.14) was
observed between class 1 and 4 (supplementary material 4).
A final analysis was performed on the different sub-
phenotypes: gender, age at diagnosis (B25 years/
[25 years), years with diagnosis (B10 years/[10 years),
Mayo-score and HB-score (mild, moderate, and severe),
extent of inflammation (proctitis, proctosigmoiditis, left-
sided colitis, pancolitis, and ileitis), smoking status
(smoking/non-smoking), extra-intestinal manifestations
(present/not present), and steroids (responder/non-respon-
der and dependent/non-dependent). This was completed by
creating PLS-DA models for each patient category; NMR
data as an X matrix and phenotype information as the Y
variables. None of the models, however, turned out to be
predictive (data not included).
4 Discussion
With the use of 1H NMR spectroscopy-based metabo-
nomics and fecal extracts from a large cohort of IBD
patients, the current study demonstrates both the possibil-
ities and limitations held by this technique as a diagnostic
tool in terms of discriminating between UC, CD, and
controls.
A recent study (Stephens et al. 2012) on urinary meta-
bolic profiles of IBD patients and healthy controls has
documented the importance of identifying confounding
factors such as medication and intestinal surgery when
using an NMR spectroscopy-based approach. Similar
results are presented in the current study, as CD and UC
patients can be distinguished from the control group
(Table 2A), but exclusion of the 8 patients who had a total
colectomy created drastic changes in the predictive results
(Table 2B). Further significant changes in the predictive
abilities were also identified with subsequent removal of
patients, who only had segmental intestinal surgery per-
formed and a preserved continuous gastrointestinal tract.
Thus, removing all patients with intestinal surgery, which
coincides with the elimination of all 8 patients receiving
TNF-a inhibitor treatment, leaves only two valid models:
active UC vs. inactive UC and active UC vs. controls
(Tables 2C and 4). In this context, it is important to note
that even minor intestinal surgery, i.e. segmental resection,
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seems to have a significant impact on the fecal
metabolome.
To further elaborate on the effect of surgery and medi-
cation subsequent predictive models of surgery versus no
surgery within each disease phenotype, i.e. inactive CD,
active CD, and inactive UC, and between different sub-
classes of inactive CD (supplementary material 4) were
created. Surprisingly, none of these models were valid.
This either indicates that an even larger cohort of patients
is needed to improve the differential power or signifies an
inherent weakness in the current approach: overlapping
drug resonances, which often leads to the exclusion of large
spectral regions and thus potential vital metabolites holding
differential power—or both. Formate, fumerate, phenylal-
anine, and tyrosine were identified in the excluded spectral
regions in the current study as potential informative and
predictive metabolites.
Recent studies have characterized the fecal metabolome
of different gastrointestinal disorders such as IBD, IBS and
colorectal cancer using mass spectrometry (MS) usually
combined with gas or liquid chromatography (Ahmed et al.
2013; Garner et al. 2007; Duboc et al. 2013). MS generally
exhibits better sensitivity, selectivity and a broader
dynamic range compared to NMR, but often requires pre-
treatment of the samples introducing additional sources of
variability to the metabonomics data. Thus, to overcome
problems with overlapping drug resonances and generally
improve the metabonomics data a combination of different
analytical technologies, e.g. NMR and MS, is needed so as
to obtain a better coverage of the metabolites and differ-
ential power.
The results of the current study are in contrast to Mar-
chesi et al. (2007) who used the exact same methodology
and were able to differentiate not only between active IBD
and controls, but also between active CD and active UC.
The metabolites holding differential power in the Marchesi
study (active CD vs. active UC) were primarily branched
chain amino acids (BCAA; isoleucine, leucine, and valine)
found in greater abundance in CD samples. The present
study also found greater abundance of BCAA and a range
Fig. 2 OPLS-DA score plots of patients without intestinal surgery.
The score plots (a and b) are based on the two valid models
containing only patients without intestinal surgery and display the 1st
PLS component and one orthogonal component for each model. A
two-way separation of the fecal samples is demonstrated in both plots.
Blue squares inactive UC; purple stars active UC; green triangles
controls. The corresponding back-scaled loading plots reflect the class
differences in the NMR spectra. Upright peaks indicate a relatively
increased intensity of metabolites, and downright peaks a decreased
intensity of metabolites. The colors shown on the plot are associated
with the significance of metabolites in separating the samples as
shown on the right hand side of the plot, where the color-scaling map
is given together with the respective correlation coefficients in
accordance with the sample number in each group and a significance
level of p \ 0.05, the metabolites are significant at correlation
coefficient values above a 0.44 and b 0.44, respectively. UC
ulcerative colitis; ala alanine; buty butyrate; ileu isoleucine; lac
lactate; leu leucine; lys lysine; prop proprionate; tau taurine; val
valine (Color figure online)
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of other amino acids (i.e. lysine, alanine, tyrosine, phen-
ylalanine, and glycine, Table 3A) in the samples from
patients with active CD and UC when compared to con-
trols, but these metabolites were without significance when
active CD and active UC were compared (Table 2A). Once
corrected for surgery (and TNF-a inhibitor treatment) the
higher abundance of BCAA, lysine, alanine, and taurine
remained evident only for active UC compare to inactive
UC and control subjects, respectively (Table 3B).
The larger amount of amino acids in active UC might
very well be due to malabsorption caused by the inflam-
mation, whereas the low levels of the short chain fatty
acids (SCFAs), butyrate and propionate, seem to be the
consequence of an inflammation-driven intestinal dysbio-
sis. Thus, a range of recent culture-independent studies
repeatedly identify Faecalibacterium prausnitzii in lower
abundance in CD (Swidsinski et al. 2009; Frank et al. 2007;
Martinez-Medina et al. 2006; Sokol et al. 2008), whereas
Clostridium coccoides has been found reduced primarily in
UC (Sokol et al. 2006; Vermeiren et al. 2012). These
species are important participants in the bacterial fermen-
tation of polysaccharides and consequently the production
of SCFAs. Usually SCFAs are produced in large amounts
reaching millimolar concentrations in the colonic lumen
from which they are absorbed (Topping and Clifton 2001).
Especially butyrate is a preferred energy source for the
colonocytes (Chapman et al. 1994) and exhibits, along with
propionate, a well documented anti-inflammatory capacity
through an inhibitory effect on TNF-a-mediated activation
of the nuclear factor (NF)-jB pathway (Tedelind et al.
2007; Segain et al. 2000). Adding insult to injury, defects
in butyrate transport across the epithelium and in the
butyrate oxidation pathway exist during inflammation in
both CD (De Preter et al. 2013) and UC (De Preter et al.
2009; Thibault et al. 2010). Thus, low levels of SCFAs
seem to be the consequence of an inflammation-driven
dysbiosis, but low levels of SCFAs by it self promote
sustained inflammation and thereby induce an uncontrolled
spiral of chronic inflammation and dysbiosis in both CD
and UC. Lactate on the other hand, is in the current study
only found in greater abundance in active UC—a result that
parallels previous studies (Hove et al. 1994; Vernia et al.
1988). Usually, lactate is not detected as a major fermen-
tation product, which is assumed to reflect the presence of
lactate-utilizing bacterial species in the microbiota of a
healthy gut (Duncan et al. 2004). Interestingly, some of the
recently identified bacterial groups of lactate-utilizing
bacteria in the human gut (i.e. E. hallii and A. caccae)
(Duncan et al. 2004) belong to the clostridial cluster XIVa,
to which C. coccoides also belong. Consequently, C. coc-
coides (lower quantity in UC) might very well represent
lactate-utilizing butyrate-producing bacteria, which could
explain the low levels of SCFAs and greater abundance of
lactate seen in active UC. In contrast, F. prausnitzii (lower
quantity in CD) is not using lactate in its production of
butyrate (Duncan et al. 2004), and no lactate increase is
detected in the samples from active CD. Hence, the met-
abolic profiles found in the fecal samples from active UC
patients consequently match the dysbiosis described by
previous studies, and the results from the current study
might accordingly be interpreted as a metabolic charac-
terization of the predominant dysbiosis in active UC.
However, the results in general need to be interpreted in
light of potential confounding factors, such as the systemic
effect of medication and changed dietary strategies during
active and inactive disease, which was not accounted for in
the current study.
In conclusion, 1H NMR spectroscopy-based metabo-
nomics on fecal extracts from IBD patients has proven to
be a potentially powerful non-invasive diagnostic tool and
able to characterize the inflammation-driven changes in the
metabolic profiles related to malabsorption and a dysbiosis
of the normal bacterial ecology. However, the study also
highlights the fact that even minor intestinal surgery, anti-
TNF-a antibody treatment, overlapping drug resonances,
and medication in general are to be accounted for in future
studies as these impose significant confounding factors;
even though it is difficult, fecal samples need to be
obtained from newly diagnosed and consequently untreated
patients, and analyzed with complementary analytical
technologies if we are ever to test the true potential of
metabonomics as a diagnostic tool in IBD.
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Table 4 Predictive capability of the models
Models corrected for surgery Area under
the curve
Active UC vs. inactive UC 0.813 Good
Active UC vs. controls 0.876 Good
Inactive UC vs. controls 0.654 Poor
Active UC vs. active CD 0.693 Poor
Inactive UC vs. inactive CD 0.659 Poor
Active CD vs. inactive CD 0.529 Poor
Active CD vs. controls 0.667 Poor
Inactive CD vs. controls 0.726 Fair
Prediction performance estimates presented as area under the curve
(AUC) for each model
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